Furthermore, targeting the hyper-inflammatory response in patients with severe COVID-19, we prepared a complete set of cytokine antibodies, such as anti–IL-6, anti–IL-8, anti–IL-10, anti–TNF-α, and anti-MCAF, which could stop inflammatory damage, and anti–TGF-β which prevent pulmonary fibrosis. This evidence concerns the gene IL6 and COVID-19.